Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GLS-5700 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Placebo | EXPERIMENTAL | Placebo at 0 mg DNA/dose |
| GLS-5700 | EXPERIMENTAL | GLS 5700 at 2 mg DNA/dose. GLS-5700 contains a single plasmid containing DNA encoding for pre-membrane and envelope (prME) proteins of the Zika virus |
| GLS-5700 at 1 mg | EXPERIMENTAL | DNA/dose |
| GLS-5700 at 2 mg | EXPERIMENTAL | DNA/dose |
| Name | Type | Description |
|---|---|---|
| GLS-5700 | BIOLOGICAL | GLS 5700 at 2 mg DNA/dose |
| Placebo | BIOLOGICAL | - |
Inclusion Criteria: * Age 18-65 years; * Able to provide consent to participate and having signed an Informed Consent Form (ICF); * Able and willing to comply with all study procedures; * Women of child-bearing potential agree to use medically effective contraception (oral contraception, barrier me...
GLS-5700 is an investigational monoclonal antibody being studied in healthy adults for the prevention of dengue virus and Zika virus infections. It is currently in Phase 1 clinical development and is not yet approved by the FDA.
GLS-5700 is being developed by Inovio Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol INO. The company is conducting clinical trials to evaluate the safety and immunogenicity of this investigational product.
GLS-5700 is in Phase 1 clinical development. Two Phase 1 trials have been completed, one in dengue virus-naïve adults and one in dengue virus seropositive adults. The drug is still investigational and has not received regulatory approval.
GLS-5700 has been studied in two completed Phase 1 trials. NCT02809443 enrolled 40 healthy adults in the United States and Canada, while NCT02887482 enrolled 160 healthy adults in Puerto Rico. Both trials were randomized, double-blind, and controlled.
GLS-5700 is a monoclonal antibody designed to target and neutralize dengue virus and Zika virus. By binding to viral proteins, it may prevent the viruses from infecting human cells, potentially offering protection against these mosquito-borne diseases.